Table 2. Clinical results.
| Results | TAC+EVR | TAC+MMF | p value |
|---|---|---|---|
| n = 20 | n = 20 | ||
| Mean Follow up (months)* | 14 ± 4 | 17 ± 5 | 0.02* |
| Lost to follow up | 0 | 1 | |
| Graft Survival (percent) | 100 | 100 | 1.00 |
| Tacrolimus level | 4.5 ± 1.9 | 6.4 ± 1.5 | 0.03 |
| Rejection episodes | 0 | 4 | 0.03* |
| Development of Denovo DSA without overt rejection | 1 | 1 | 1.00 |
| Proteinuria > 1g/day | 2 | 2 | 1.00 |
| Adverse Events | |||
| Hypertriglyceridemia | 3 | 1 | 0.33 |
| BK nephropathy | 0 | 1 | 1.00 |
| Neutropenia | 0 | 1 | 1.00 |
| Other Infections** | 5 | 3 | 0.44 |
* Results expressed as mean ± standard deviation. Please see Table A in S4 File for complete information.
** Other infections included bacteremia, clostridium difficile colitis, abdominal abscess and herpes zoster